Daniel L Van Dyke
Overview
Explore the profile of Daniel L Van Dyke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
1282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hampel P, Rabe K, Wang Y, Hwang S, Kenderian S, Muchtar E, et al.
Leukemia
. 2024 Dec;
39(2):503-507.
PMID: 39658628
No abstract available.
2.
Wiedmeier-Nutor J, McCabe C, OBrien D, Jessen E, de Campos C, Boddicker N, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001512
Chronic lymphocytic leukemia (CLL) is characterized by multiple copy number alterations (CNAs) and somatic mutations that are central to disease prognosis, risk stratification, and mechanisms of therapy resistance. Fluorescence in...
3.
Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
Griffin R, Wiedmeier-Nutor J, Parikh S, McCabe C, OBrien D, Boddicker N, et al.
Blood Adv
. 2023 Mar;
7(13):3169-3179.
PMID: 36877634
TP53 aberrations, including mutations and deletion of 17p13, are important adverse prognostic markers in chronic lymphocytic leukemia (CLL) but are less studied in high count monoclonal B-cell lymphocytosis (HCMBL), an...
4.
Hampel P, Rabe K, Call T, Ding W, Leis J, Chanan-Khan A, et al.
Blood Cancer J
. 2022 Sep;
12(9):124.
PMID: 36050317
Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. A better understanding of expected outcomes in these...
5.
Gagnon M, Berg H, Meyer R, Sukov W, Van Dyke D, Jenkins R, et al.
Genes Chromosomes Cancer
. 2022 May;
61(10):629-634.
PMID: 35639830
The diagnosis of acute promyelocytic leukemia (APL) relies on the identification of PML::RARA fusion. While the majority of APL cases harbor a typical t(15;17)(q24;q21), atypical genetic mechanisms leading to the...
6.
Kay N, Hampel P, Van Dyke D, Parikh S
Blood Rev
. 2022 Feb;
54:100930.
PMID: 35151528
Chronic lymphocytic leukemia (CLL) is diagnosed by the presence of a specific immunophenotype of clonal B cells in the peripheral blood. Prognostic models such as the CLL-International Prognostic Index (CLL-IPI)...
7.
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome
Wang H, Tian S, Zhao Q, Blumenschein W, Yearley J, Secreto C, et al.
Hematol Oncol
. 2021 Nov;
40(2):302-306.
PMID: 34806797
No abstract available.
8.
Koleilat A, McGarrah P, Olteanu H, Van Dyke D, Smadbeck J, Johnson S, et al.
Cancer Genet
. 2021 Nov;
260-261:1-5.
PMID: 34781094
The t(4;12)(q12;p13) has been rarely reported in both myeloid/lymphoid neoplasms with eosinophilia (ETV6/PDGFRA gene fusion) and acute myeloid leukemia (AML) (ETV6/CHIC2 gene fusion). The ability to accurately characterize t(4;12) is...
9.
Wu X, Nowakowski K, Abeykoon J, Manske M, Stenson M, Timm M, et al.
Eur J Haematol
. 2021 Jul;
107(4):458-465.
PMID: 34214199
Background: Despite the unprecedented success of ibrutinib in lymphoma therapy, the development of ibrutinib resistance due to acquired BTK or PLCγ2 mutations has become a new clinical problem. However, not...
10.
Wang Y, Sinha S, Wellik L, Secreto C, Rech K, Call T, et al.
Blood Cancer J
. 2021 May;
11(5):86.
PMID: 33972504
Richter syndrome (RS) refers to transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. RS is known to be associated with a number...